These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 29740438)

  • 1. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
    Cerboni C; Ardolino M; Santoni A; Zingoni A
    Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
    Kim Y; Born C; Bléry M; Steinle A
    Front Immunol; 2020; 11():960. PubMed ID: 32582150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
    Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
    Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.
    Magri G; Muntasell A; Romo N; Sáez-Borderías A; Pende D; Geraghty DE; Hengel H; Angulo A; Moretta A; López-Botet M
    Blood; 2011 Jan; 117(3):848-56. PubMed ID: 21030563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
    Ding H; Yang X; Wei Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NKG2D axis: an emerging target in cancer immunotherapy.
    Lazarova M; Steinle A
    Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
    Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
    Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
    Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
    Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.
    Baragaño Raneros A; Martín-Palanco V; Fernandez AF; Rodriguez RM; Fraga MF; Lopez-Larrea C; Suarez-Alvarez B
    Genes Immun; 2015; 16(1):71-82. PubMed ID: 25393931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis.
    Legroux L; Moratalla AC; Laurent C; Deblois G; Verstraeten SL; Arbour N
    Front Immunol; 2019; 10():154. PubMed ID: 30787931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
    Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
    Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of NKG2D/NKG2D ligand interaction attenuated cardiac remodelling after myocardial infarction.
    Matsumoto K; Obana M; Kobayashi A; Kihara M; Shioi G; Miyagawa S; Maeda M; Sakata Y; Nakayama H; Sawa Y; Fujio Y
    Cardiovasc Res; 2019 Mar; 115(4):765-775. PubMed ID: 30307485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
    Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
    Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.